The National Cancer Institute (NCI) is offering this grant to support innovative biospecimen science technologies. This grant aims to improve the quality and handling of samples for basic and clinical cancer research and care. Its primary purpose is to address pre-analytical degradation during biospecimen collection, processing, handling, and storage. NCI seeks tools and methods that preserve sample integrity, establish quality assessment, and maximize sample utility for downstream analyses. These innovations are expected to accelerate cancer biology, detection, diagnosis, treatment, and epidemiology research, while addressing health disparities.
Opportunity ID: 357735
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-CA-25-003 |
| Funding Opportunity Title: | Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | 4 |
| Assistance Listings: | 93.394 — Cancer Detection and Diagnosis Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Dec 16, 2024 |
| Last Updated Date: | Dec 16, 2024 |
| Original Closing Date for Applications: | Oct 03, 2025 |
| Current Closing Date for Applications: | Oct 03, 2025 |
| Archive Date: | Nov 08, 2025 |
| Estimated Total Program Funding: | $150,000 |
| Award Ceiling: | $150,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Native American tribal governments (Federally recognized) For profit organizations other than small businesses Private institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) City or township governments County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments Small businesses Others (see text field entitled “Additional Information on Eligibility” for clarification) Public housing authorities/Indian housing authorities Special district governments Public and State controlled institutions of higher education Independent school districts |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies to improve the quality and handling of samples used for cancer research or clinical care. This includes tools with new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This NOFO will support the development of tools, devices, instrumentation, and associated methods for the collection, handling, processing, preservation, or storage of cancer-relevant biospecimens and their derivatives. This includes tools with new capabilities to preserve or protect sample integrity, establish verification criteria for quality assessment/quality control, and address issues related to pre-analytical degradation of target analytes. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, or epidemiology, and/or address issues associated with cancer health disparities. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-25-003.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 357735 Full Announcement-RFA-CA-25-003 -> RFA-CA-25-003-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-I | Use for due dates on or after January 25, 2025 | PKG00289679 | Mar 04, 2025 | Oct 03, 2025 | View |
Package 1
Mandatory forms
357735 RR_SF424_5_0-5.0.pdf
357735 PHS398_CoverPageSupplement_5_0-5.0.pdf
357735 RR_OtherProjectInfo_1_4-1.4.pdf
357735 PerformanceSite_4_0-4.0.pdf
357735 RR_KeyPersonExpanded_4_0-4.0.pdf
357735 PHS398_ResearchPlan_5_0-5.0.pdf
357735 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
357735 RR_Budget_3_0-3.0.pdf
357735 RR_SubawardBudget30_3_0-3.0.pdf
357735 PHS398_ModularBudget_1_2-1.2.pdf
357735 PHS_AssignmentRequestForm_4_0-4.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
